EGLN3
| Official symbol: | EGLN3 |
| Full name: | egl-9 family hypoxia inducible factor 3 |
| Location: | 14q13.1 |
| Also known as: | HIFPH3, PHD3 |
| Entrez ID: | 112399 |
| Ensembl ID: | ENSG00000129521 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
| Expression restricted in 1 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.00 |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 3 |
|
|
| Fusions detected in 3 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
CRISPR: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 119.05 (Percentile rank: 75.16%) |
| PubTator score: | 88.43 (Percentile rank: 76.03%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
| Tractability (antibody): | |
